Overview of COVID-19 Therapeutics and Prophylaxis for Non-Hospitalized Patients

The resources below provide:
  1. Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
  2. Comparison table of treatment options.
  3. How providers may obtain these treatments or prophylaxis for their patients.
  4. Where providers can refer their patients for infusion therapies.
  5. Reporting requirements.

Treatment

*Adapted from COCA call 1/22/22
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.

Prophylaxis

Evusheld
Description
  • Evusheld is a monoclonal antibody combination approved for use as a Pre-exposure Prophylaxis for those who are unable to receive or are not expected to mount an immune response with vaccines.
  • Distribution should be prioritized to hospitals that offer special services such as oncology and rheumatology, etc. Providers who care for such patients should refer to these centers for access to this product.
Patient Profiles
  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents).

Become a Provider

HHS currently distributes an allocation of  Paxlovid and Molnupiravir to each state. All medications must be ordered through the Health Partners Order Portal (HPOP).
  1. Sign up with HPOP here.
  2. If you need help getting set up, email DPH.MABTherapy@illinois.gov

Locate Therapeutics and Prophylaxis In The City

  • Infusion Providers Accepting External Referrals:
Provider
Contact Information:
AMITA Health Saints Mary and Elizabeth Medical Center Tel: 312-770-8534
Fax: 312-770-3182
John H Stroger Jr Hospital of Cook County covidtherapeutics@cookcountyhhs.org
Provident Hospital of Chicago covidtherapeutics@cookcountyhhs.org
Saint Anthony Hospital ttruesdell@sahchicago.org
Swedish Covenant Hospital Tel: 773-907-7700
​​​​​​
  • Test to Treat in Chicago
  • Providers who don’t want to receive allocations can use the ASPR COVID-19 Therapeutics Locator to find providers, pharmacies and infusion centers with doses on hand.
  • For providers looking for immediate access to COVID-19 Therapeutics, available doses may be found on the IDPH Matchmaker Site. If you are a provider and have extra doses in between distribution cycles, please use this site so others have access.

State and Federal Reporting Requirements

Reporting into Health Partner Ordering Portal (HPOP)
  • Report utilization and doses on hand of Paxlovid and Legevrio at least twice a month by 11:59ET pm on the 15th and last day of the month. Report on hand doses of all other therapeutics once a month by 11:59ET pm the last day of the month.
  • When reporting utilization of each product, report the quantity used since the last report. Do not report the cumulative amount over time.
  • For any issues related to ordering or reporting of HPOP therapeutics, reach out to cars_helpdesk@cdc.gov or 833-748-1979
  • Click here (https://aspr.hhs.gov/COVID-19/Therapeutics/Distribution/Pages/process-for-ordering.aspx) for more information on HPOP reporting.

Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
 

Provider Resource Library and Other Useful Links

Shelf life Extensions

Shelf-Life Extension infomation. Click the links to view the affected lot numbers.

New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
 
Sites interested in providing USG-purchased COVID-19 therapeutics, sign up for the Health Partners Ordering Portal here

TREAT COVID-19

The Chicago Department of Health has partnered with the Chicago Internal Medicine Practice and Research (CIMPAR S.C.) for the TREAT COVID-19 program. CIMPAR S.C. will provide onsite mobile treatment and infection prevention services to LTCF residents of Medicare/Medicaid certified nursing homes and assisted living facilities who test positive for Covid-19.  See flyer for details